+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Kadmon Corporation - logo

Kadmon is a fully integrated biopharmaceutical company that focuses on small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Its lead product candidates is KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases. The company is headquartered in New York.

From
From
From
Psoriasis (Immunology) - Drugs In Development, 2021 - Product Thumbnail Image

Psoriasis (Immunology) - Drugs In Development, 2021

  • Report
  • July 2021
  • 1178 Pages
From
Global Scleroderma Therapeutics Market 2022-2026 - Product Thumbnail Image

Global Scleroderma Therapeutics Market 2022-2026

  • Report
  • March 2022
  • 120 Pages
From
Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2020 - Product Thumbnail Image

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 419 Pages
From
Scleroderma - Pipeline Insight, 2021 - Product Thumbnail Image

Scleroderma - Pipeline Insight, 2021

  • Clinical Trials
  • May 2021
  • 100 Pages
From
From
From
From
From
From
From
Psoriasis - Pipeline Insight, 2021 - Product Thumbnail Image

Psoriasis - Pipeline Insight, 2021

  • Clinical Trials
  • May 2021
  • 200 Pages
From
From
From
From
Loading Indicator